2023
Variation in neutrophil levels and artemisinin-based combination therapy efficacy in West-Africa.
Djimde M, Kayentao K, Tshiongo J, Fofana B, Arama C, Sirima S, Ouedraogo J, Beavogui A, Sagara I, Dicko A, Mens P, Schallig H, Djimde A. Variation in neutrophil levels and artemisinin-based combination therapy efficacy in West-Africa. The Journal Of Infection In Developing Countries 2023, 17: 1337-1345. PMID: 37824364, DOI: 10.3855/jidc.17089.Peer-Reviewed Original ResearchConceptsArtemisinin-based combination therapyNormal neutrophil countsPolymorphonuclear neutrophilsDay 28Neutropenia groupPyronaridine-ArtesunateNeutrophil countNeutrophil levelsDifferent artemisinin-based combination therapiesRole of PMNsCombination therapy efficacyP. falciparum parasitemiaPositive blood smearPlasmodium falciparum parasitemiaLevels of neutrophilsAL armASAQ armProspective longitudinalRecurrent parasitemiaCombination therapyNeutrophil rateNeutropenia patientsNormal ratePatientsPathogen clearance
2021
Persistent Submicroscopic Plasmodium falciparum Parasitemia 72 Hours after Treatment with Artemether-Lumefantrine Predicts 42-Day Treatment Failure in Mali and Burkina Faso
Beshir K, Diallo N, Somé F, Sombie S, Zongo I, Fofana B, Traore A, Dama S, Bamadio A, Traore O, Coulibaly S, Maurice O, Diarra A, Kaboré J, Kodio A, Togo A, Dara N, Coulibaly M, Dao F, Nikiema F, Compaore Y, Kabore N, Barry N, Soulama I, Sagara I, Sirima S, Ouédraogo J, Djimde A, Sutherland C. Persistent Submicroscopic Plasmodium falciparum Parasitemia 72 Hours after Treatment with Artemether-Lumefantrine Predicts 42-Day Treatment Failure in Mali and Burkina Faso. Antimicrobial Agents And Chemotherapy 2021, 65: 10.1128/aac.00873-21. PMID: 34060901, PMCID: PMC8284475, DOI: 10.1128/aac.00873-21.Peer-Reviewed Original ResearchConceptsArtemether-lumefantrineClinical episodesFirst treatment episodeComplete parasite clearanceDrug treatment groupPlasmodium falciparum parasitemiaQuantitative PCRMalaria transmission intensityEvaluable patientsParasitological efficacyParasite clearanceTreatment failureSubmicroscopic parasitemiaTreatment episodesTreatment outcomesTreatment groupsBetter efficacyDay 42Short intervalsH posttreatmentParasitemiaRegimensPatientsBurkina FasoTransmission intensity
2019
Genetically diverse Plasmodium falciparum infections, within-host competition and symptomatic malaria in humans
Sondo P, Derra K, Lefevre T, Diallo-Nakanabo S, Tarnagda Z, Zampa O, Kazienga A, Valea I, Sorgho H, Ouedraogo J, Guiguemde T, Tinto H. Genetically diverse Plasmodium falciparum infections, within-host competition and symptomatic malaria in humans. Scientific Reports 2019, 9: 127. PMID: 30644435, PMCID: PMC6333925, DOI: 10.1038/s41598-018-36493-y.Peer-Reviewed Original ResearchConceptsParasite densityMalaria symptomsHemoglobin levelsP. falciparum genetic diversityMixed infectionsMAD20 allelic familyMono-infected individualsLower hemoglobin levelsPlasmodium falciparum infectionAllelic familiesLow parasite densitiesP. falciparum isolatesMixed strain infectionsFC27 allelesSymptomatic malariaOlder patientsFalciparum infectionYounger patientsPharmacovigilance studyFalciparum isolatesHigh parasitaemiaP. falciparumPolymorphic antigensPatientsInfection
2018
Plasmodium falciparum msp1 and msp2 genetic diversity and allele frequencies in parasites isolated from symptomatic malaria patients in Bobo-Dioulasso, Burkina Faso
Somé A, Bazié T, Zongo I, Yerbanga R, Nikiéma F, Neya C, Taho L, Ouédraogo J. Plasmodium falciparum msp1 and msp2 genetic diversity and allele frequencies in parasites isolated from symptomatic malaria patients in Bobo-Dioulasso, Burkina Faso. Parasites & Vectors 2018, 11: 323. PMID: 29843783, PMCID: PMC5975679, DOI: 10.1186/s13071-018-2895-4.Peer-Reviewed Original ResearchConceptsSymptomatic malaria patientsPolymerase chain reactionMalaria patientsAllelic familiesBobo-DioulassoMAD20 allelic familyUrban health centersCause of morbidityMerozoite surface protein 1K1 allelic familySurface protein 1Plasmodium falciparum msp1P. malariaUncomplicated malariaFalciparum infectionResultsA totalHealth centersBlood samplesP. falciparumConclusionsOur studyBlood spotsMalaria parasite populationsAllele frequenciesPatientsBurkina Faso
2016
A Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms
Ménard D, Khim N, Beghain J, Adegnika A, Shafiul-Alam M, Amodu O, Rahim-Awab G, Barnadas C, Berry A, Boum Y, Bustos M, Cao J, Chen J, Collet L, Cui L, Thakur G, Dieye A, Djallé D, Dorkenoo M, Eboumbou-Moukoko C, Espino F, Fandeur T, Ferreira-da-Cruz M, Fola A, Fuehrer H, Hassan A, Herrera S, Hongvanthong B, Houzé S, Ibrahim M, Jahirul-Karim M, Jiang L, Kano S, Ali-Khan W, Khanthavong M, Kremsner P, Lacerda M, Leang R, Leelawong M, Li M, Lin K, Mazarati J, Ménard S, Morlais I, Muhindo-Mavoko H, Musset L, Na-Bangchang K, Nambozi M, Niaré K, Noedl H, Ouédraogo J, Pillai D, Pradines B, Quang-Phuc B, Ramharter M, Randrianarivelojosia M, Sattabongkot J, Sheikh-Omar A, Silué K, Sirima S, Sutherland C, Syafruddin D, Tahar R, Tang L, Touré O, Tshibangu-wa-Tshibangu P, Vigan-Womas I, Warsame M, Wini L, Zakeri S, Kim S, Eam R, Berne L, Khean C, Chy S, Ken M, Loch K, Canier L, Duru V, Legrand E, Barale J, Stokes B, Straimer J, Witkowski B, Fidock D, Rogier C, Ringwald P, Ariey F, Mercereau-Puijalon O. A Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms. New England Journal Of Medicine 2016, 374: 2453-2464. PMID: 27332904, PMCID: PMC4955562, DOI: 10.1056/nejmoa1513137.Peer-Reviewed Original ResearchConceptsK13 mutationsRing-stage survival assayK13-propeller polymorphismsPlasmodium falciparum resistanceA578S mutationParasite clearanceRare nonsynonymous mutationsFalciparum resistanceAntimalarial resistanceArtemisinin resistanceNationwide surveillanceGlobal burdenSentinel sitesGeographic disparitiesSurvival assaysP. falciparum genesMalariaPropeller domainMajor determinantArtemisininMutationsNonsynonymous mutationsSuch resistancePolymorphismPatients
2014
Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors That Affect Treatment Outcomes for P. falciparum Malaria After Artemether-Lumefantrine and Artesunate-Amodiaquine
Venkatesan M, Gadalla N, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, Price R, Mårtensson A, Rosenthal P, Dorsey G, Sutherland C, Guérin P, Davis T, Ménard D, Adam I, Ademowo G, Arze C, Baliraine F, Berens-Riha N, Björkman A, Borrmann S, Checchi F, Desai M, Dhorda M, Djimdé A, El-Sayed B, Eshetu T, Eyase F, Falade C, Faucher J, Fröberg G, Grivoyannis A, Hamour S, Houzé S, Johnson J, Kamugisha E, Kariuki S, Kiechel J, Kironde F, Kofoed P, LeBras J, Malmberg M, Mwai L, Ngasala B, Nosten F, Nsobya S, Nzila A, Oguike M, Otienoburu S, Ogutu B, Ouédraogo J, Piola P, Rombo L, Schramm B, Somé A, Thwing J, Ursing J, Wong R, Zeynudin A, Zongo I, Plowe C, Sibley C, Asaq Molecular Marker Study Group. Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors That Affect Treatment Outcomes for P. falciparum Malaria After Artemether-Lumefantrine and Artesunate-Amodiaquine. American Journal Of Tropical Medicine And Hygiene 2014, 91: 833-843. PMID: 25048375, PMCID: PMC4183414, DOI: 10.4269/ajtmh.14-0031.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SubstitutionAmodiaquineAntimalarialsArtemetherArtemisininsChildChild, PreschoolChloroquineDatasets as TopicDrug CombinationsDrug ResistanceDrug Therapy, CombinationEthanolaminesFluorenesGenetic MarkersGenotypeHumansInfantKaplan-Meier EstimateLumefantrineMalaria, FalciparumMembrane Transport ProteinsMultidrug Resistance-Associated ProteinsPlasmodium falciparumPolymorphism, GeneticProtozoan ProteinsRisk FactorsConceptsArtemether-lumefantrineP. falciparum multidrug resistance 1 genePlasmodium falciparum chloroquine resistance transporterPfmdr1 copy numberArtemisinin combination therapyIndividual patient dataChloroquine resistance transporterMultidrug resistance 1 geneWorldWide Antimalarial Resistance NetworkParasitologic cureCombination therapyParasite polymorphismsPartner drugsTherapeutic responseClinical trialsRelevant outcomesArtemisinin componentPatient dataResistance transporterStandardized methodPolymorphismPatientsPfmdr1PfcrtAmodiaquine
2013
Anti-Pfs25 Human Plasma Reduces Transmission of Plasmodium falciparum Isolates That Have Diverse Genetic Backgrounds
Da D, Dixit S, Sattabonkot J, Mu J, Abate L, Ramineni B, Ouedraogo J, MacDonald N, Fay M, Su X, Cohuet A, Wu Y. Anti-Pfs25 Human Plasma Reduces Transmission of Plasmodium falciparum Isolates That Have Diverse Genetic Backgrounds. Infection And Immunity 2013, 81: 1984-1989. PMID: 23509152, PMCID: PMC3676035, DOI: 10.1128/iai.00016-13.Peer-Reviewed Original ResearchConceptsPhase 1 trialParasite isolatesMalaria transmission-blocking vaccineTransmission-reducing activityTransmission-blocking activityPlasmodium falciparum isolatesTransmission-blocking vaccinesPlasmodium falciparum parasitesLimited sequence polymorphismPfs25 antibodiesMontanide ISA51Immune plasmaNonimmune controlsRecombinant Pfs25Falciparum isolatesPfs25 geneFalciparum parasitesGenetic backgroundPatientsBurkina FasoPfs25VaccineTrialsNucleotide polymorphismsIsolates
2012
<i>Neisseria meningitis</i> serogroup X outbreak in Burkina Faso, 2009-2010
Yaro S, Drabo A, Ouangraoua S, Kirakoya-Samadoulougou F, Mueller J, Sanou O, Tall H, Jaillard P, Njanpop-Lafourcade B, Macq J, Robert A, Ouedraogo J. Neisseria meningitis serogroup X outbreak in Burkina Faso, 2009-2010. Open Journal Of Internal Medicine 2012, 2012: 41-49. DOI: 10.4236/ojim.2012.22010.Peer-Reviewed Original ResearchVaccine introductionPolymerase chain reactionSerogroup XPneumococcal vaccine introductionContacts of patientsReference laboratoryCountries' national guidelinesPilot districtsAdequate antibioticsCentre MurazCampaign vaccinationSecondary casesPolyvalent vaccineSerogroup distributionFluid collectionNational guidelinesVaccine compositionCSF samplesEpidemiological seasonFaster careLaboratory capacityAttack rateChain reactionBobo-DioulassoPatients
2010
Sociological perspectives on the management of TB/HIV co-infection in Burkina Faso.
Zerbo R, Drabo K, Kouanda S, Ouedraogo J, Dujardin B, Macq J, Huygens P. Sociological perspectives on the management of TB/HIV co-infection in Burkina Faso. Cahiers De Santé 2010, 20: 195-9. PMID: 21282097, DOI: 10.1684/san.2010.0206.Peer-Reviewed Original ResearchConceptsSocio-anthropological studyTB/HIVSociological perspectiveEconomic insecurityNegative social imagesSocial relationsSocial integrationBurkina FasoSocial stigmaMarginalisationPublic health projectsAnti-TB drugsDouble burdenSocial imageHealth ProjectHealth care systemIll patientsDaily dosesHealth districtHealth centersBiomedical issuesCare practicesPatientsPainful experiencesDifficult treatment
2008
Chloroquine‐resistance molecular markers (Pfcrt T76 and Pfmdr‐1 Y86) and amodiaquine resistance in Burkina Faso
Tinto H, Guekoun L, Zongo I, Guiguemdé R, D’Alessandro U, Ouédraogo J. Chloroquine‐resistance molecular markers (Pfcrt T76 and Pfmdr‐1 Y86) and amodiaquine resistance in Burkina Faso. Tropical Medicine And International Health 2008, 13: 238-240. PMID: 18304270, DOI: 10.1111/j.1365-3156.2007.01995.x.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAmodiaquineAnimalsAntimalarialsBurkina FasoChildChild, PreschoolChloroquineDrug ResistanceHumansInfantInfant, NewbornMalaria, FalciparumMembrane Transport ProteinsMultidrug Resistance-Associated ProteinsMutationPlasmodium falciparumPolymerase Chain ReactionPrevalenceProtozoan ProteinsTreatment FailureTreatment Outcome
2007
Sulfadoxine-pyrimethamine efficacy and selection of Plasmodium falciparum DHFR mutations in Burkina Faso before its introduction as intermittent preventive treatment for pregnant women.
Tinto H, Ouédraogo J, Zongo I, van Overmeir C, van Marck E, Guiguemdé T, D'Alessandro U. Sulfadoxine-pyrimethamine efficacy and selection of Plasmodium falciparum DHFR mutations in Burkina Faso before its introduction as intermittent preventive treatment for pregnant women. American Journal Of Tropical Medicine And Hygiene 2007, 76: 608-13. PMID: 17426157, DOI: 10.4269/ajtmh.2007.76.608.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAnimalsAntimalarialsBurkina FasoChildChild, PreschoolChloroquineDrug Administration ScheduleDrug CombinationsDrug ResistanceFemaleGenotypeHumansInfantMalaria, FalciparumMaleMutationPlasmodium falciparumPregnancyPregnancy Complications, ParasiticPyrimethamineSelection, GeneticSulfadoxineTetrahydrofolate DehydrogenaseConceptsSulfadoxine-pyrimethamine efficacyTriple dhfr mutationDHFR mutationsRecurrent parasitemiaIntermittent preventive treatmentSulfadoxine-pyrimethamine resistanceYears of ageSuch high prevalenceDihydropteroate synthetase (Pfdhps) mutationsPCR-restriction fragment length polymorphismSulfadoxine-pyrimethamineTreatment failurePregnant womenPolymerase chain reactionPreventive treatmentHigh prevalenceNew infectionsChain reactionMutant parasitesPatientsParasitemiaTreatmentFragment length polymorphismPrevalenceEfficacyArtemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial
Zongo I, Dorsey G, Rouamba N, Tinto H, Dokomajilar C, Guiguemde R, Rosenthal P, Ouedraogo J. Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. The Lancet 2007, 369: 491-498. PMID: 17292769, DOI: 10.1016/s0140-6736(07)60236-0.Peer-Reviewed Original ResearchConceptsUncomplicated falciparum malariaTreatment failureUncomplicated malariaArtemether-lumefantrineRecurrent parasitaemiaFalciparum malariaNew infectionsArtemisinin-based combination treatmentLate treatment failureEarly treatment failureNon-inferiority trialSymptomatic malariaEffective regimensPrimary endpointCombination regimensStandard dosesAvailable regimenCombination treatmentDrug susceptibilityPatientsAmodiaquineMalarial treatmentMalariaRegimensBobo-DioulassoAn action research network to improve the quality of tuberculosis care in West Africa.
Drabo M, Dauby C, Macq J, Seck I, Ouendo E, Sani I, Traoré A, Kouamé P, Ouedraogo J, Dujardin B. An action research network to improve the quality of tuberculosis care in West Africa. Cahiers De Santé 2007, 17: 79-86. PMID: 17962155.Peer-Reviewed Original ResearchConceptsTB program managersCare providersTB patientsTuberculosis careCase managementCare systemTuberculosis case managementTB detection ratesHigh-quality careHealth care systemHealth system managersResearch NetworkNational Health SystemDistrict medical officersPoor complianceOne-year periodHealth systemPatientsCareMedical officersProgram managersLack of accessDetection rateProvidersResearch team
2006
Decentralising tuberculosis case management in two districts of Burkina Faso.
Drabo K, Dauby C, Coste T, Dembelé M, Hien C, Ouedraogo A, Macq J, Ouedraogo J, Dujardin B. Decentralising tuberculosis case management in two districts of Burkina Faso. The International Journal Of Tuberculosis And Lung Disease 2006, 10: 93-8. PMID: 16466044.Peer-Reviewed Original ResearchConceptsNational Tuberculosis ProgrammeCase managementTB suspectsSmear-positive TB casesPrimary health care centersTuberculosis case managementTB case managementHealth care centersHealth care delivery systemCare delivery systemConfirmation of TBChronic coughTB casesTuberculosis ProgrammeDistrict hospitalCare centerDetection rateCase detectionBurkina FasoCase management systemDelivery systemTBCoughPatientsHospital
2003
Malaria: use of restriction endonuclease digestion and mutation-specific PCR for antifolate resistance isolate detection.
Kengne P, Ouédraogo J, Zampan H, Veas F, Guiguemdé T. Malaria: use of restriction endonuclease digestion and mutation-specific PCR for antifolate resistance isolate detection. Parassitologia 2003, 45: 27-31. PMID: 15270541.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SubstitutionAnimalsAntimalarialsDNA Mutational AnalysisDNA, ProtozoanDrug ResistanceFolic Acid AntagonistsHumansMalaria, FalciparumMutation, MissenseParasitemiaPlasmodium falciparumPoint MutationPolymerase Chain ReactionPolymorphism, Restriction Fragment LengthProguanilProtozoan ProteinsPyrimethamineTetrahydrofolate DehydrogenaseConceptsMutation-specific PCRCycloguanil resistanceBlood samplesResistance isolatesResistance mutationsPlasmodium falciparumMixed infectionsChemosensitivity analysisBloodWhole bloodParasite lysateRapid DNA extractionPCR productsRestriction endonuclease digestionPCRAmplified productsDry filter paperPCR technologyPoint mutationsEndonuclease digestionUndigested samplesPatientsInfectionPyrimethamineMutations
2001
In vitro susceptibility of 232 isolates of Plasmodium falciparum to antimalarials in Burkina Faso (West Africa).
Tinto H, Ouedraogo J, Traoré B, Coulibaly S, Guiguemde T. In vitro susceptibility of 232 isolates of Plasmodium falciparum to antimalarials in Burkina Faso (West Africa). Bulletin De La Société De Pathologie Exotique 2001, 94: 188-91. PMID: 16579075.Peer-Reviewed Original ResearchConceptsP. falciparumPlasmodium falciparumCells/mm3Chloroquine-resistant strainsInclusion criteriaReference centerParasite countsSingle infectionResistant isolatesSignificant positive correlationParasite growthPersistence of resistanceFalciparumHalofantrineBobo-DioulassoSignificant increaseMefloquineIC50 valuesPositive correlationIsolatesQuinineSusceptibilityPatientsBurkina FasoIncubation periodPreliminary study of cutaneous leishmaniasis in the town of Ouagadougou from 1996 to 1998.
Traoré K, Sawadogo N, Traoré A, Ouedraogo J, Traoré K, Guiguemdé T. Preliminary study of cutaneous leishmaniasis in the town of Ouagadougou from 1996 to 1998. Bulletin De La Société De Pathologie Exotique 2001, 94: 52-5. PMID: 11346985.Peer-Reviewed Original ResearchConceptsCutaneous leishmaniasisClinical formsHealth centersMonths of progressionAge of patientsFrequent clinical formPublic Health CenterDifferent clinical formsSite of infectionHealth care staffReports of casesProtocol therapyProspective studyRetrospective studyMean ageLocal etiologyInferior limbHigh incidenceCommon locationPatientsCare staffClinical casesCase managementDecisional algorithmLeishmaniasis
1997
Esquisse d'une méthode d'estimation du coût économique chiffré des accès palustres: application à une zone rurale au Burkina Faso (Afrique de l'Ouest)
Guiguemdé T, Coulibaly N, Coulibaly S, Ouedraogo J, Gbary A. Esquisse d'une méthode d'estimation du coût économique chiffré des accès palustres: application à une zone rurale au Burkina Faso (Afrique de l'Ouest). Tropical Medicine And International Health 1997, 2: 646-653. PMID: 9289349, DOI: 10.1046/j.1365-3156.1997.d01-351.x.Peer-Reviewed Original ResearchConceptsDuration of illnessIndirect costsDirect costsHealth center clientsCosts of malariaAccount direct costsAge of subjectsMost patientsConsultation feesAverage durationDegree of invalidityMicroscopic examinationBurkina FasoCenter clientsIllnessMalariaAdultsChildrenYearsDurationMedicationsRural areasPatients
1996
How to perform and interpret the results of a chemoresistance test of Plasmodium falciparum in malaria patients in a tropical region.
Guiguemdé R, Gbary R, Coulibaly S, Ouedraogo J. How to perform and interpret the results of a chemoresistance test of Plasmodium falciparum in malaria patients in a tropical region. Cahiers De Santé 1996, 6: 187-91. PMID: 8764454.Peer-Reviewed Original Research
1991
Preliminary epidemiological study of dracunculosis in the southwest of Burkina Faso.
Gbary A, Ouedraogo J, Guiguemde T. Preliminary epidemiological study of dracunculosis in the southwest of Burkina Faso. Medecine Tropicale 1991, 51: 263-7. PMID: 1834910.Peer-Reviewed Original Research